Non-VKA oral anticoagulants: Accurate measurement of plasma drug concentrations

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Douxfils, Jonathan ^a   Mani, Helen ^b   Minet, Valentine ^a   Devalet, Bérangère ^a   Chatelain, Bernard ^a   Dogné, Jean Michel ^a   Mullier, François ^a  

^a University of Namur   (Belgium)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; DABIGATRAN; RIVAROXABAN; ANTICOAGULANT AGENT; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; THIOPHENE DERIVATIVE;

ANTICOAGULATION; BLEEDING; BLOOD CLOTTING TEST; DRUG BLOOD LEVEL; HUMAN; MEASUREMENT ACCURACY; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; REVIEW; TREATMENT RESPONSE; BLOOD CLOTTING; CHEMICALLY INDUCED; DRUG EFFECTS; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK ASSESSMENT; THROMBOEMBOLISM;

ANTICOAGULANTS; BLOOD COAGULATION; DABIGATRAN; HEMORRHAGE; HUMANS; MORPHOLINES; PYRAZOLES; PYRIDONES; RISK ASSESSMENT; RIVAROXABAN; THIOPHENES; THROMBOEMBOLISM;

EID: 84930958955     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/345138     Document Type: Review

References (82)

1. S. Bloemen, M. De Laat, B. De Laat, H. C. Hemker, and R. Al Dieri, Will one size of anticoagulant dosage fit all? Drug Development Research, vol. 74, no. 7, pp. 406-412, 2013.
2. H. ten Cate, New oral anticoagulants: discussion on monitoring and adherence should start now!, Thrombosis Journal, vol. 11, no. 1, article 8, 2013.
3. European Medicine Agency-Xarelto, Summary of Product Characteristics, 2013, http://www.ema.europa.eu/docs/en GB/ document library/EPAR -Product Information/000944/WC5-00057108.pdf.
4. European Medicine Agency-Pradaxa, Summary of Product Characteristics, 2014, http://www.ema.europa.eu/docs/en GB/ document library/EPAR -Product Information/human/0008-29/WC500041059.pdf.
5. European Medicine Agency, Eliquis: Summary of Product Characteristics 2014, http://www.ema.europa.eu/docs/en GB/ document library/EPAR -Product Information/human/0021-48/WC500107728.pdf.
6. Food and Drug Administration-Pradaxa, Full Prescribing Information, 2013, http://www.accessdata.fda.gov/drugsatfda docs/label/2013/022512s017lbl.pdf
7. Food and Drug Administration, Xarelto: Full Prescribing Information, 2014, http://www.accessdata.fda.gov/drugsatfda docs/label/2013/022406s004lbl.pdf.
8. Food and Drug Administration, Eliquis: Full Prescribing Information, 2014, http://www.accessdata.fda.gov/drugsatfda docs/label/2012/202155s000lbl.pdf.
9. E. Nutescu, I. Chuatrisorn, and E. Hellenbart, Drug and dietary interactions of warfarin and novel oral anticoagulants: an update, Journal ofThrombosis andThrombolysis, vol. 31, no. 3, pp. 326-343, 2011.
10. T. A. Leil, C. Frost, X.Wang, M. Pfister, and F. LaCreta, Modelbased exposure-response analysis of apixaban to quantify bleeding risk in special populations of subjects undergoing orthopedic surgery, CPT: Pharmacometrics & Systems Pharmacology, vol. 3, p. e136, 2014.
11. K.-H. Liesenfeld, T. Lehr, C. Dansirikul et al., Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate inpatientswithnon-valvular atrial fibrillation fromthe RE-LY trial, Journal of Thrombosis and Haemostasis, vol. 9, no. 11, pp. 2168-2175, 2011.
12. W. Mueck, J. Stampfuss, D. Kubitza, and M. Becka, Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban, Clinical Pharmacokinetics, vol. 53, no. 1, pp. 1-16, 2014.
13. P. Mismetti and S. Laporte, New oral antithrombotics: a need for laboratory monitoring. For, Journal of Thrombosis and Haemostasis, vol. 8, no. 4, pp. 621-626, 2010.
14. H. ten Cate, Monitoring new oral anticoagulants, managing thrombosis, or both? Thrombosis & Haemostasis, vol. 107, no. 5, pp. 803-805, 2012.
15. G. Paré, N. Eriksson, T. Lehr et al., Genetic determinants of dabigatran plasma levels and their relation to bleeding, Circulation, vol. 127, no. 13, pp. 1404-1412, 2013.
16. P. A. Reilly, T. Lehr, S. Haertter et al., The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY trial (Randomized Evaluation of Long-Term Anticoagulation Therapy), Journal of the American College of Cardiology, vol. 63, no. 4, pp. 321-328, 2014.
17. Food and Drug Administration, Xarelto: Clinical Pharmacology & Biopharmaceutical Review(s), 2009, http://www.accessdata. fda.gov/drugsatfda docs/nda/2011/022406Orig1s000Clin-PharmR.pdf.
18. Food and drug Administration, Eliquis: Clinical Pharmacology & Biopharmaceutical Review(s), 2012, http://www.accessdata. fda.gov/drugsat fda docs/nda/2012/202155Orig1s000Clin-PharmR.pdf
19. M.Ehrenschwender, J. Koessler,K.Brunner, andU.Steigerwald, A77-year-oldmanwith a prolonged activated partial thromboplastin time, Clinical Chemistry, vol. 58, no. 10, pp. 1402-1407, 2012.
20. M. Legrand, J. Mateo, A. Aribaud et al., The use of dabigatran in elderly patients, Archives of Internal Medicine, vol. 171, no. 14, pp. 1285-1286, 2011.
21. A. L.-L. Louët, M. Wolf, L. Soufir et al., Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation, Thrombosis and Haemostasis, vol. 108, no. 3, pp. 583-585, 2012.
22. A. Schattner, N. Kozak, and J. Friedman, Fatality in a patient treated with dabigatran, The American Journal of Emergency Medicine, vol. 31, no. 2, pp. 443.e1-443.e2, 2013.
23. K. Yokoi, K. Isoda, T. Kimura, and T. Adachi, Diffuse alveolar hemorrhage associated with dabigatran, InternalMedicine, vol. 51, no. 18, pp. 2667-2668, 2012.
24. H. Bounameaux and G. Reber, New oral antithrombotics: a need for laboratorymonitoring. Against, Journal ofThrombosis and Haemostasis, vol. 8, no. 4, pp. 627-630, 2010.
25. V. Pengo, L. Crippa, A. Falanga et al., Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results, Journal of Thrombosis and Haemostasis, vol. 10, no. 10, pp. 1979-1987, 2012.
26. H. Mani and E. Lindhoff-Last, New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness, Drug Design, Development and Therapy, vol. 8, pp. 789-798, 2014.
27. A. G. G. Turpie, R. Kreutz, J. Llau, B. Norrving, and S. Haas, Management consensus guidance for the use of rivaroxaban-an oral, direct factor Xa inhibitor,Thrombosis andHaemostasis, vol. 108, no. 5, pp. 876-886, 2012.
28. K. Huber, K. J. Airaksinen, T. Cuisset, F. Marín, A. Rubboli, and G. Y.H. Lip, Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities betweenNorth America and Europe, Thrombosis & Haemostasis, vol. 106, no. 4, pp. 569-571, 2011.
29. D. P. Faxon, J. W. Eikelboom, P. B. Berger et al., Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective, Thrombosis and Haemostasis, vol. 106, no. 4, pp. 572-584, 2011.
30. D. M. Adcock, Sample integrity and preanalytical variables, in Quality in LaboratoryHemostasis andThrombosis, S.O. Kitchen, J. D. Olson, and E. F. Preston, Eds., pp. 45-56, John Wiley & Sons, Blackwell Publishing, 2nd edition, 2013.
31. T. Baglin, A. Hillarp, A. Tripodi, I. Elalamy, H. Buller, and W. Ageno, Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis, Journal of Thrombosis and Haemostasis, vol. 11, no. 4, pp. 756-760, 2013.
32. J. Douxfils, F.Mullier, S. Robert, C. Chatelain, B. Chatelain, and J.-M. Dogné, Impact of dabigatran on a large panel of routine or specific coagulation assays: laboratory recommendations for monitoring of dabigatran etexilate, Thrombosis and Haemostasis, vol. 107, no. 5, pp. 985-997, 2012.
33. M. Van Blerk, E. Bailleul, B. Chatelain et al., Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey, Thrombosis and Haemostasis, vol. 112, p. 6, 2014.
34. J. P. Antovic, M. Skeppholm, J. Eintrei et al., Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma, European Journal of Clinical Pharmacology, vol. 69, no. 11, pp. 1875-1881, 2013.
35. J. Douxfils, J.-M. Dogné, F. Mullier et al., Comparison of calibrated dilute thrombin time and aPTT tests with LCMS/ MS for the therapeutic monitoring of patients treated with dabigatran etexilate,Thrombosis and Haemostasis, vol. 110, no. 3, pp. 543-549, 2013.
36. E. M. Hawes, A. M. Deal, D. Funk-Adcock et al., Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels, Journal of Thrombosis and Haemostasis, vol. 11, no. 8, pp. 1493-1502, 2013.
37. G. Hapgood, J. Butler, E. Malan, S. Chunilal, and H. Tran, The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the hemoclot thrombin inhibitor assay in patient plasma samples, Thrombosis and Haemostasis, vol. 110, no. 2, pp. 308-315, 2013.
38. G. Lippi, G. L. Salvagno, L. Ippolito, M. Franchini, and E. J. Favaloro, Shortened activated partial thromboplastin time: causes and management, Blood Coagulation and Fibrinolysis, vol. 21, no. 5, pp. 459-463, 2010.
39. C. S. Kitchens, To bleed or not to bleed? Is that the question for the PTT? Journal ofThrombosis andHaemostasis, vol. 3, no. 12, pp. 2607-2611, 2005.
40. J. W. Eikelboom and J. Hirsh, Monitoring unfractionated heparin with the aPTT: time for a fresh look, Thrombosis & Haemostasis, vol. 96, no. 5, pp. 547-552, 2006.
41. J. Hirsh, T. E.Warkentin, S. G. Shaughnessy et al., Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety, Chest, vol. 119, no. 1, pp. 64S-94S, 2001.
42. W. Mueck, L. C. Borris, O. E. Dahl et al., Population pharmacokinetics and pharmacodynamics of once-and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement, Thrombosis and Haemostasis, vol. 100, no. 3, pp. 453-461, 2008.
43. W. Mueck, B. I. Eriksson, K. A. Bauer et al., Population pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor-in patients undergoing major orthopaedic surgery, Clinical Pharmacokinetics, vol. 47, no. 3, pp. 203-216, 2008.
44. A. Tripodi, V. Chantarangkul, C. Guinet, and M. M. Samama, The InternationalNormalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study, Journal of Thrombosis and Haemostasis, vol. 9, no. 1, pp. 226-228, 2011.
45. T. Baglin, The role of the laboratory in treatment with new oral anticoagulants, Journal ofThrombosis and Haemostasis, vol. 11, no. 1, pp. 122-128, 2013.
46. Y. C. Barrett, Z. Wang, C. Frost, and A. Shenker, Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay, Thrombosis and Haemostasis, vol. 104, no. 6, pp. 1263-1271, 2010.
47. M. M. Samama, J.-L.Martinoli, L. LeFlem et al., Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor, Thrombosis and Haemostasis, vol. 103, no. 4, pp. 815-825, 2010.
48. A.Hillarp, F. Baghaei, I. F. Blixter et al., Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays, Journal of Thrombosis and Haemostasis, vol. 9, no. 1, pp. 133-139, 2011.
49. J. Douxfils, F. Mullier, C. Loosen, C. Chatelain, B. Chatelain, and J. M. Dogné, Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature, Thrombosis Research, vol. 130, no. 6, pp. 956-966, 2012.
50. J. Douxfils, A. Tamigniau, B. Chatelain et al., Comparison of calibrated chromogenic anti-Xa assay and PT tests with LCMS/ MS for the therapeutic monitoring of patients treated with rivaroxaban, Thrombosis and Haemostasis, vol. 110, no. 4, pp. 723-731, 2013.
51. J. J. van Veen, J. Smith, S. Kitchen, and M. Makris, Normal prothrombin time in the presence of therapeutic levels of rivaroxaban, British Journal of Haematology, vol. 160, no. 6, pp. 859-861, 2013.
52. R. Rodgers, C. N. Bagot, C. Lawrence, G.Hickman,M.Mcgurk, and R. C. Tait, Correlating prothrombin time with plasma rivaroxaban level, British Journal of Haematology, vol. 163, no. 5, pp. 685-687, 2013.
53. J. Harenberg, S. Du, C. Weiss, R. Krämer, D. Hoppensteadt, and J. Walenga, Report of the Subcommittee on Control of Anticoagulation on the determination of the anticoagulant effects of apixaban: communication from the SSC of the ISTH, Journal of Thrombosis and Haemostasis, vol. 12, no. 5, pp. 801-804, 2014.
54. R. C. Becker, J. H. Alexander, L. K. Newby et al., Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome, Thrombosis and Haemostasis, vol. 104, no. 5, pp. 976-983, 2010.
55. J. Douxfils, C. Chatelain, B. Chatelain, J.-M. Dogné, and F. Mullier, Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide, Thrombosis and Haemostasis, vol. 110, no. 2, pp. 283-294, 2013.
56. C. Frost, S. Nepal, J.Wang et al., Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects, British Journal of Clinical Pharmacology, vol. 76, no. 5, pp. 776-786, 2013.
57. I. Gouin-Thibault, C. Flaujac, X. Delavenne et al., Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre french GEHT study, Thrombosis &Haemostasis, vol. 111, no. 2, pp. 240-248, 2014.
58. G. W. Moore, Recent guidelines and recommendations for laboratory detection of lupus anticoagulants, Seminars in Thrombosis and Hemostasis, vol. 40, no. 2, pp. 163-171, 2014.
59. G. M. A. van Os, B. de Laat, P. W. Kamphuisen, J. C. M. Meijers, and P. G. de Groot, Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venomtime, Journal of Thrombosis and Haemostasis, vol. 9, no. 8, pp. 1657-1659, 2011.
60. E.Merriman, Z.Kaplan, J. Butler, E.Malan, E. Gan, andH. Tran, Rivaroxaban and false positive lupus anticoagulant testing, Thrombosis and Haemostasis, vol. 105, no. 2, pp. 385-386, 2011.
61. T. Exner, L. Ellwood, J. Rubie, and A. Barancewicz, Testing for new oral anticoagulants with LA-resistant Russells viper venom reagents. An in vitro study, Thrombosis and Haemostasis, vol. 109, no. 4, pp. 762-765, 2013.
62. R.Altman andC.D.Gonzalez, Simple and rapid assay for effect of the neworal anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs, Thrombosis Journal, vol. 12, no. 1, article 7, 2014.
63. J.Van Ryn, J. Stangier, S.Haertter et al., Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity, Thrombosis and Haemostasis, vol. 103, no. 6, pp. 1116-1127, 2010.
64. J. Stangier and M. Feuring, Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran, Blood Coagulation and Fibrinolysis, vol. 23, no. 2, pp. 138-143, 2012.
65. R. C. Gosselin, D. M. Dwyre, and W. E. Dager, Measuring dabigatran concentrations using a chromogenic ecarin clotting time assay, The Annals of Pharmacotherapy, vol. 47, no. 12, pp. 1635-1640, 2013.
66. G. Nowak, The ecarin clotting time, a universal method to quantify direct thrombin inhibitors, Pathophysiology of Haemostasis andThrombosis, vol. 33, no. 4, pp. 173-183, 2003.
67. U. Lange, G. Nowak, and E. Bucha, Ecarin chromogenic assay-a new method for quantitative determination of direct thrombin inhibitors like hirudin, Pathophysiology ofHaemostasis andThrombosis, vol. 33, no. 4, pp. 184-191, 2003.
68. J.Douxfils, A. Tamigniau, B.Chatelain, C.Goffinet, J.M.Dogne, and F. Mullier, Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays, Thrombosis Journal, vol. 12, article 24, 2014.
69. D. Kubitza, M. Becka, G.Wensing, B. Voith, andM. Zuehlsdorf, Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects, European Journal of Clinical Pharmacology, vol. 61, no. 12, pp. 873-880, 2005.
70. M. M. Samama, J. Amiral, C. Guinet, E. Perzborn, and F. Depasse, An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma, Thrombosis andHaemostasis, vol. 104, no. 5,pp. 1078-1079, 2010.
71. L. M. Asmis, L. Alberio, A. Angelillo-Scherrer et al., Rivaroxaban: quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories, Thrombosis Research, vol. 129, no. 4, pp. 492-498, 2012.
72. G. T. Gerotziafas, I. Elalamy, F. Depasse, E. Perzborn, and M. M. Samama, In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban, Journal of Thrombosis and Haemostasis, vol. 5, no. 4, pp. 886-888, 2007.
73. J. Harenberg, R. Krämer, C. Giese, S. Marx, C.Weiss, and M. Wehling, Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability, Journal of Thrombosis andThrombolysis, vol. 32, no. 3, pp. 267-271, 2011.
74. H. Mani, C. Hesse, G. Stratmann, and E. Lindhoff-Last, Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time, Thrombosis and Haemostasis, vol. 106, no. 1, pp. 156-164, 2011.
75. H. Mani, G. Rohde, G. Stratmann et al., Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin, Thrombosis & Haemostasis, vol. 108, no. 1, pp. 191-198, 2012.
76. M. M. Samama, G. Contant, T. E. Spiro et al., Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls,Thrombosis and Haemostasis, vol. 107, no. 2, pp. 379-387, 2012.
77. S. J. Francart, E. M. Hawes, A. M. Deal et al., Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels,Thrombosis and Haemostasis, vol. 111, no. 6, pp. 1133-1140, 2014.
78. R. C. Becker, H. Yang, Y. Barrett et al., Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban-an oral, direct and selective factor Xa inhibitor, Journal of Thrombosis andThrombolysis, vol. 32, no. 2, pp. 183-187, 2011.
79. J.Harenberg, S. Du, S. Krämer et al., Novel methods for assessing oral direct factor xa and thrombin inhibitors: use of pointof-care testing and urine samples, Seminars inThrombosis and Hemostasis, vol. 39, no. 1, pp. 66-71, 2013.
80. J. Harenberg, S. Krämer, S. Du, C. Weiss, and R. Krämer, Concept of a point of care test to detect neworal anticoagulants in urine samples,Thrombosis Journal, vol. 11, article 15, 2013.
81. J. Harenberg, S. Kramer, S. Du et al., Measurement of rivaroxaban and apixaban in serum samples of patients, European Journal of Clinical Investigation, vol. 44, pp. 743-752, 2014.
82. G. Pernod, P. Albaladejo, A. Godier et al., Management of major bleeding complications and emergency surgery in patients on long-termtreatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the Working Group on Perioperative Haemostasis (GIHP) -March 2013, Archives of Cardiovascular Diseases, vol. 106, no. 6-7, pp. 382-393, 2013.